Skip to content

Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children

Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03539913
Acronym
SABINA
Enrollment
317
Registered
2018-05-30
Start date
2017-06-19
Completion date
2018-06-09
Last updated
2019-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Gastroenteritis

Brief summary

* Primary Objective: o To assess the efficacy of the probiotics in reducing the duration of diarrhea in children suffering from acute gastroenteritis. * Secondary Objectives: * To assess the efficacy of the probiotics in improving the frequency and consistency of stools. * To assess the efficacy of the probiotics in avoiding recurrence of diarrhea. * To assess the efficacy of the probiotics on the disease severity. * To assess the safety and tolerability of the studied probiotics.

Interventions

BIOLOGICALProbiotic : Saccharomyces boulardii

Treatment for 5 days

BIOLOGICALProbiotic : Bacillus clausii

Treatment for 5 days

Sponsors

Biocodex
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Masking description

Allocation-blinded study

Eligibility

Sex/Gender
ALL
Age
6 Months to 5 Years
Healthy volunteers
No

Inclusion criteria

* Children of both gender aged between 6 months and 5 years * Presenting with acute diarrhea (3 or more loose or liquid stools in a 24-hour period) since at least the last 24h but less than 5 days * Signed informed consent of the legal representatives obtained before any study procedure * Parents able to fulfill in the stool diary according to the physician's opinion.

Exclusion criteria

* Unable to take medication and fluids by mouth * More than 50% breastfeeding * Severe malnutrition, defined by a ratio weight/height at/or below -3SD * Severe dehydration, defined by a need of IV rehydration * Chronic underlying disease, including but not limited to severe gastrointestinal disorder, immunocompromised condition or systemic infection * Use of prohibited treatments * Contra-indications to the studied probiotics

Design outcomes

Primary

MeasureTime frameDescription
Time frame in hours up to the time of the last liquid or loose stool as recorded in the stool diary5 daysTime frame in hours up to the time of the last liquid or loose stoll (defined as type 6 or 7 on Bristol Stool Scale) followed by the first 24-hour period with stool consistency improvement (no liquid or loose stool), i.e. cessation of diarrhea as recorded by the parents in the stool diary.

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026